Lactobacillus plantarum 299

Lactobacillus plantarum 299v is a clinically studied probiotic strain that produces lactic acid and adheres to intestinal mucosa via mannose-specific adhesins, competitively excluding pathogens and modulating gut barrier function. Its primary mechanism involves reducing intestinal permeability, suppressing pro-inflammatory cytokines such as TNF-α and IL-6, and normalizing bowel motility in irritable bowel syndrome.

Origin & History

Lactobacillus plantarum 299v (LP299V or DSM 9843) is a specific probiotic strain isolated from human intestinal mucosa and developed for clinical use in the early 1990s. Despite the species name, it originates from the human gut microbiome rather than plants and is produced through fermentation processes typical for probiotic strains. As a live microorganism belonging to the lactic acid bacteria (Firmicutes phylum), it has been patented and commercialized for gastrointestinal applications.

Historical & Cultural Context

L. plantarum 299v has no traditional or historical use, as it is a patented strain clinically developed in the 1990s. Unlike many probiotics with roots in traditional fermented foods, this specific strain was isolated directly from human intestinal mucosa for therapeutic purposes.

Health Benefits

• Reduces IBS symptoms: In a 214-patient RCT, pain severity decreased by 45.2% vs. 23.3% placebo, with 78.1% rating efficacy as good/excellent (strong evidence, PMID: 22912552)
• Resolves abdominal pain: 100% of IBS patients treated achieved pain resolution vs. 45% placebo in a 40-patient RCT (moderate evidence, PMID: 11711768)
• Improves bloating and colonic fermentation: Significant improvements at weeks 3-4 in IBS patients (moderate evidence, PMID: 12452404)
• May reduce C. difficile recurrence: Fewer recurrences with metronidazole + LP299v (4/11) vs. metronidazole alone (6/9) (preliminary evidence, PMID: 12953945)
• Enhances vascular function: Improved endothelial function and reduced inflammation in coronary artery disease patients (preliminary evidence, PMID: 30355158)

How It Works

Lactobacillus plantarum 299v adheres to colonic epithelial cells via mannose-specific adhesins, competitively displacing pathogenic bacteria and reinforcing tight-junction proteins including occludin and ZO-1 to reduce intestinal permeability. It downregulates NF-κB signaling, decreasing production of pro-inflammatory cytokines TNF-α, IL-6, and IL-1β while promoting anti-inflammatory IL-10 secretion from regulatory T cells. The strain also produces short-chain fatty acids, particularly butyrate, which serve as fuel for colonocytes and further stabilize the mucosal barrier.

Scientific Research

Multiple randomized controlled trials support L. plantarum 299v for IBS symptom relief, with the largest multicenter RCT (n=214, PMID: 22912552) showing significant reductions in pain and bloating over 4 weeks. However, one hospital-based RCT (PMID: 25194614) found no benefit over placebo at 8 weeks, possibly due to large placebo effects. Additional trials demonstrate benefits for colonic fermentation (PMID: 12452404), C. difficile-associated diarrhea (PMID: 12953945), and vascular function (PMID: 30355158).

Clinical Summary

A 214-patient randomized controlled trial (PMID: 22912552) demonstrated that Lactobacillus plantarum 299v reduced IBS pain severity by 45.2% compared to 23.3% in the placebo group, with 78.1% of treated patients rating efficacy as good or excellent, representing strong evidence for symptom relief. A smaller 40-patient RCT showed 100% abdominal pain resolution in treated IBS patients versus 45% in the placebo arm, though the modest sample size warrants moderate confidence in this finding. Evidence is strongest for IBS-related abdominal pain and bloating, with less robust data for diarrhea-predominant subtypes and conditions outside the gastrointestinal tract. Overall, the clinical profile of this strain is among the most extensively validated of any single probiotic strain in gastrointestinal research.

Nutritional Profile

Lactobacillus plantarum 299 is a viable probiotic bacterium, not a significant source of macronutrients or micronutrients in conventional dietary terms. Typical therapeutic doses range from 5×10⁹ to 10×10⁹ CFU (colony-forming units) per serving, as used in clinical studies (PMID: 22912552). As a bacterial organism, each cell contributes negligible caloric value (<1 kcal per dose). Bioactive compounds of note include: cell wall components such as lipoteichoic acid and peptidoglycan fragments, which interact with host toll-like receptors (TLR-2) to modulate immune signaling; surface-layer proteins (Slp) that facilitate adhesion to intestinal epithelial mannose receptors; and bacteriocin-like inhibitory substances (BLIS) that confer competitive exclusion against pathogens. L. plantarum 299 produces short-chain fatty acids (SCFAs) — primarily lactic acid (D- and L-isomers), with minor acetic acid production — during fermentation of dietary substrates in the colon, contributing to luminal pH reduction and intestinal barrier support. The strain produces B-group vitamins during metabolism, including folate (B9) and riboflavin (B2), though quantities delivered per probiotic dose are clinically negligible. Bioavailability context: the strain demonstrates documented gastric acid and bile salt tolerance, with survival rates through the GI tract sufficient to achieve live colonization of the colon, a key factor distinguishing it from many probiotic strains. No significant protein, fat, or dietary fiber content is delivered at standard probiotic doses.

Preparation & Dosage

Clinically studied dose: 10^10 CFU/day (10 billion colony-forming units), typically as two 5×10^9 CFU capsules daily. Available in fermented milk, capsules, or powder forms. Standard treatment duration in IBS trials: 4-8 weeks. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Prebiotics (FOS/GOS), Digestive enzymes, Peppermint oil, Glutamine, Slippery elm

Safety & Interactions

Lactobacillus plantarum 299v is generally recognized as safe, with adverse events in clinical trials limited to mild, transient gastrointestinal symptoms such as bloating and flatulence that typically resolve within the first week of use. Individuals who are immunocompromised, have short bowel syndrome, or have central venous catheters should consult a physician before use, as rare cases of bacteremia have been reported with probiotic strains in high-risk populations. No clinically significant drug interactions have been formally established, though concurrent use with broad-spectrum antibiotics will reduce colonization efficacy and should be temporally separated by at least two hours. Safety data in pregnancy and lactation are limited; while the strain is considered low-risk, pregnant individuals should seek medical guidance before supplementation.